Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > REGULATORY
REGULATORY
- Kamoshita Tapped as Advisor to PM on Drug, Dementia Policies
September 27, 2023
- Aichi Case of Death After COVID Shot Could Have Been Avoided with Adequate Steps: Report
September 27, 2023
- Japan to Balance Innovation, Finances in Leqembi Pricing: Minister
September 27, 2023
- Draft Revision of Basic Blood Product Policy OK’ed, to Be Finalized by March-End
September 27, 2023
- Leqembi Approval Marks New Era of Dementia Treatment: Japan PM
September 26, 2023
- Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
September 26, 2023
- Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
- Govt Must Bolster Leadership in Building Drug Discovery Ecosystem: New Minister
September 26, 2023
- Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
- Japan PM Announces Yen-Loan Program to Fight Pandemics
September 25, 2023
- Ex-Minister Tamura Tapped for No. 2 in LDP Policy Panel
September 25, 2023
- METI to Bankroll 95.5 Billion Yen in 23 Projects to Build Vaccine Sites, Moderna Among Them
September 22, 2023
- MHLW Panel Members Call for Tightening Advertising Regulations for Off-Label GLP-1 Use
September 22, 2023
- Sitagliptin Increases Cancer Risk in 1 in 115,000 People with Current Global Impurity Limit: Makers
September 22, 2023
- Chuikyo Rep Grumbles at Too Many Industry Requests, FPMAJ Chief Wants Health Coverage Dabate
September 21, 2023
- Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- Japan Launches Fall COVID-19 Vaccination Campaign
September 21, 2023
- Apply Brand-Based Price Revisions to Qualified Generic Makers: JGA
September 21, 2023
- JPWA Urges Price Hikes for Drugs with NHI Tag Below 20 Yen
September 21, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…